HOME ·

LEPU BIO

LEPU BIO(02157.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 27.39 million, YoY decrease of 34.38%
Tags：
LEPU BIO02157.HK
2026-08-19
LEPU BIO (02157.HK): Global Phase III Trial of CMG901 Meets Primary Endpoint, Significantly Improves Overall Survival of CLDN18.2-positive Advanced Gastric Cancer Patients
Tags：
LEPU BIO02157.HKAstraZenecaClinical Trial
2026-07-28
LEPU BIO (02157.HK): Employee Representative Supervisor Zhao Lixuan Resigned, Ren Fangyuan Appointed as Successor
Tags：
LEPU BIO02157.HKSupervisor Change
2026-07-15